{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:21:14Z","timestamp":1780669274574,"version":"3.54.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD) is a chronic inflammatory disorder with increasing worldwide incidence and prevalence. While current treatment options alleviate part of the socioeconomic burden of this disease, new biomarkers and safer therapeutic approaches are needed to combat intestinal inflammation. Class-3 semaphorins (sema3A-3G) have emerged as important regulators of some biological functions underlying inflammation. For instance, SEMA3B protects against tissue damage in arthritis. However, the association of this protein with UC and its involvement in the onset of intestinal inflammation remains elusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To close that knowledge gap, we performed a comprehensive transcriptomic analysis of different patient cohorts. Moreover, we investigated the therapeutic efficacy of Sema3B\n                      <jats:italic>in vivo<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our findings revealed that the expression of\n                      <jats:italic>SEMA3B<\/jats:italic>\n                      was downregulated in IBD patients compared with healthy controls. Similarly, non-responder UC patients to infliximab showed reduced transcript levels of that class-3 semaphorin before receiving the treatment. Unfortunately, the administration of recombinant Sema3B to mice subjected to DSS-acute colitis did not modify the course of the disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Therefore, SEMA3B appears to be an interesting biomarker in the context of intestinal inflammation, which deserves further validation in larger cohorts. Nonetheless, based on our\n                      <jats:italic>in vivo<\/jats:italic>\n                      results, the implication of this factor in the development of colitis seems to be minimal.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1677130","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:34:09Z","timestamp":1770183249000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo"],"prefix":"10.3389","volume":"17","author":[{"given":"Laura","family":"Arosa","sequence":"first","affiliation":[{"name":"Molecular and Cellular Gastroenterology Group, Health Research Institute of Santiago de Compostela (IDIS)","place":["Santiago de Compostela, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Malvar-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Rheumatology & Immuno-mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO","place":["Vigo, Spain"]},{"name":"Rheumatology Department, University Hospital of Vigo","place":["Vigo, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Ant\u00fanez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Clinical Hospital of Santiago de Compostela","place":["Santiago de Compostela, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Rheumatology & Immuno-mediated Diseases Research Group (IRIDIS), Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO","place":["Vigo, Spain"]},{"name":"Rheumatology Department, University Hospital of Vigo","place":["Vigo, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Conde-Aranda","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Gastroenterology Group, Health Research Institute of Santiago de Compostela (IDIS)","place":["Santiago de Compostela, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00634","article-title":"Semaphorin3A: A potential therapeutic tool for lupus nephritis","volume":"9","author":"Bejar","year":"2018","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903527","article-title":"The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis","volume":"185","author":"Catalano","year":"2010","journal-title":"J Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19915","article-title":"Adenovirus-mediated delivery of Sema3A alleviates rheumatoid arthritis in a serum-transfer induced mouse model","volume":"8","author":"Teng","year":"2017","journal-title":"Oncotarget"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.04.031","article-title":"Expression of semaphorin 3E is suppressed in severe asthma","volume":"140","author":"Movassagh","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601514","article-title":"Semaphorin 3E deficiency exacerbates airway inflammation, hyperresponsiveness, and remodeling in a mouse model of allergic asthma","volume":"198","author":"Movassagh","year":"2017","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14614","article-title":"Semaphorin-3E attenuates intestinal inflammation through the regulation of the communication between splenic CD11C + and CD4 + CD25 \u2013 T-cells","volume":"176","author":"Kermarrec","year":"2019","journal-title":"Br J Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex511","article-title":"Class 3 semaphorins modulate the invasive capacity of rheumatoid arthritis fibroblast-like synoviocytes","volume":"57","author":"Tang","year":"2018","journal-title":"Rheumatol (Oxford)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1268144","article-title":"Semaphorin3B promotes an anti-inflammatory and pro-resolving phenotype in macrophages from rheumatoid arthritis patients in a MerTK-dependent manner","volume":"14","author":"Mart\u00ednez-Ramos","year":"2023","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/art.42065","article-title":"Central role of semaphorin 3B in a serum-induced arthritis model and reduced levels in patients with rheumatoid arthritis","volume":"74","author":"Igea","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303333","article-title":"Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations","volume":"62","author":"Planell","year":"2013","journal-title":"Gut"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000535","article-title":"Strong upregulation of AIM2 and IFI16 inflammasomes in the mucosa of patients with active inflammatory bowel disease","volume":"21","author":"Vanhove","year":"2015","journal-title":"Inflammation Bowel Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e7984","DOI":"10.1371\/journal.pone.0007984","article-title":"Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment","volume":"4","author":"Arijs","year":"2009","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/gutjnl-2016-312293","article-title":"Effect of vedolizumab (anti-\u03b14\u03b27-integrin) therapy on histological healing and mucosal gene expression in patients with UC","volume":"67","author":"Arijs","year":"2018","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111439","article-title":"Cytokine responsive networks in human colonic epithelial organoids unveil a molecular classification of inflammatory bowel disease","volume":"40","author":"Pavlidis","year":"2022","journal-title":"Cell Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13073-022-01112-z","article-title":"Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease","volume":"14","author":"Mishra","year":"2022","journal-title":"Genome Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.cgh.2019.08.030","article-title":"Expression levels of 4 genes in colon tissue might be used to predict which patients will enter endoscopic remission after vedolizumab therapy for inflammatory bowel diseases","volume":"18","author":"Verstockt","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.01.027","article-title":"Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease","volume":"40","author":"Verstockt","year":"2019","journal-title":"EBioMedicine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/THNO.54023","article-title":"Semaphorins as emerging clinical biomarkers and therapeutic targets in cancer","volume":"11","author":"Mastrantonio","year":"2021","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00681.2023","article-title":"SEMA3B inhibits TGF\u03b2-induced extracellular matrix protein production and its reduced levels are associated with a decline in lung function in IPF","volume":"326","author":"Yombo","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac654","article-title":"HOXA5 is a key regulator of class 3 semaphorins expression in the synovium of rheumatoid arthritis patients","volume":"62","author":"Mart\u00ednez-Ramos","year":"2023","journal-title":"Rheumatol (United Kingdom)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/diagnostics11101902","article-title":"A multi-mrna prognostic signature for anti-tnf\u03b1 therapy response in patients with inflammatory bowel disease","volume":"11","author":"Sakaram","year":"2021","journal-title":"Diagnostics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad060","article-title":"Novel mRNA signature for anti-TNF-\u03b1 Therapy primary response in patients with ulcerative colitis","volume":"29","author":"Yang","year":"2023","journal-title":"Inflammation Bowel Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/life13030680","article-title":"Identification of specific biomarkers and pathways in the treatment response of infliximab for inflammatory bowel disease: in-silico analysis","volume":"13","author":"Kaddoura","year":"2023","journal-title":"Life"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.3.1601","article-title":"Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis","volume":"167","author":"Wipke","year":"2001","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200526167","article-title":"A crucial role for macrophages in the pathology of K\/B \u00d7 N serum-induced arthritis","volume":"35","author":"Solomon","year":"2005","journal-title":"Eur J Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-022-02817-7","article-title":"Semaphorin 3G exacerbates joint inflammation through the accumulation and proliferation of macrophages in the synovium","volume":"24","author":"Shoda","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109649","article-title":"Semaphorin3C identified as mediator of neuroinflammation and microglia polarization after spinal cord injury","volume":"27","author":"Shen","year":"2024","journal-title":"iScience"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI130834","article-title":"Semaphorin 3F signaling actively retains neutrophils at sites of inflammation","volume":"130","author":"Plant","year":"2020","journal-title":"J Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000407","article-title":"Semaphorin 3C exacerbates liver fibrosis","volume":"78","author":"De Angelis Rigotti","year":"2023","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601093","article-title":"Chemorepellent semaphorin 3E negatively regulates neutrophil migration in vitro and in vivo","volume":"198","author":"Movassagh","year":"2017","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011778","article-title":"Semaphorin 7A coordinates neutrophil response during pulmonary inflammation and sepsis","volume":"8","author":"Granja","year":"2024","journal-title":"Blood Adv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.08.073","article-title":"Aggravation of different types of experimental colitis by depletion or adhesion blockade of neutrophils","volume":"133","author":"K\u00fchl","year":"2007","journal-title":"Gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1997.tb00375.x","article-title":"Selective depletion of neutrophils by a monoclonal antibody, RP-3, suppresses dextran sulphate sodium-induced colitis in rats","volume":"12","author":"Natsui","year":"1997","journal-title":"J Gastroenterol Hepatol (Australia)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/S41575-023-00871-3","article-title":"Neutrophils: from IBD to the gut microbiota","volume":"21","author":"Danne","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1677130\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T05:34:10Z","timestamp":1770183250000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1677130\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2026.1677130"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1677130","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"article-number":"1677130"}}